GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » 3-Year EPS without NRI Growth Rate

Sino Biopharmaceutical (HKSE:01177) 3-Year EPS without NRI Growth Rate : -8.70% (As of Jun. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical 3-Year EPS without NRI Growth Rate?

Sino Biopharmaceutical's EPS without NRI for the six months ended in Jun. 2024 was HK$0.08.

During the past 12 months, Sino Biopharmaceutical's average EPS without NRI Growth Rate was 60.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was -8.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -2.80% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Sino Biopharmaceutical was 108.00% per year. The lowest was -31.90% per year. And the median was 18.25% per year.


Competitive Comparison of Sino Biopharmaceutical's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Sino Biopharmaceutical's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's 3-Year EPS without NRI Growth Rate falls into.


;
;

Sino Biopharmaceutical 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Sino Biopharmaceutical  (HKSE:01177) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Sino Biopharmaceutical 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Sino Biopharmaceutical Business Description

Traded in Other Exchanges
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2023, 37.8% of the firm's total revenue comes from five innovative drugs and five biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 33.6% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.
Executives
Tse Ping 2101 Beneficial owner
Tse Eric S Y 2101 Beneficial owner
Cheng Cheung Ling 2101 Beneficial owner
True Merit Global Limited 2101 Beneficial owner
Tse Theresa Y Y 2101 Beneficial owner
Thousand Eagles Limited 2101 Beneficial owner
France Investment (china 1) Group Limited 2101 Beneficial owner
Remarkable Industries Limited 2101 Beneficial owner
Validated Profits Limited 2101 Beneficial owner

Sino Biopharmaceutical Headlines

No Headlines